BACKGROUND Diffuse Midline Gliomas (DMGs) present formidable challenges in neuro-
oncology, prompting the exploration of innovative therapeutic strategies. Repurposing …

Diffuse midline gliomas (DMG), including those of the brainstem (diffuse intrinsic pontine
glioma-DIPG), are pediatric CNS tumors recognized as the most lethal of all children's …

Abstract INTRODUCTION DMG-ACT (DMG-multi-arm A daptive and C ombinatorial T rial)
aims to implement a highly innovative clinical trial design of combinatorial arms for patients …

Diffuse midline gliomas (DMG) are driven by self-renewing, stem-like glioma cells stalled in
an oligodendrocyte precursor cell (OPC)-like state that are characterized by high expression …

BACKGROUND Diffuse midline glioma (DMG) is a universally fatal CNS tumor, with a
median overall survival of< 12-months. Recent studies, including our own, have identified …

Diffuse midline gliomas (DMGs) remain incurable cancers and new treatments are urgently
needed. One promising new therapeutic avenue for these cancers is targeting of metabolic …

Abstract Diffuse Intrinsic Pontine Glioma (DIPG) remains to be a lethal type of pediatric brain
tumor to date, indicating an urgent need of finding novel therapeutic strategy. Through …

DIPG is the leading cause of brain tumor-related death in children. Currently, radiation is the
only treatment that offers transient benefit. Compared to normal brain tissue, DIPGs are …

BACKGROUND Diffuse midline gliomas (DMG) are uniformly fatal pediatric brain cancers,
refractory to current standards of care. Based on genomic and transcriptomic profiling data …

Pediatric diffuse midline gliomas (DMGs), including diffuse intrinsic pontine glioma (DIPG),
are the most difficult childhood brain cancers to treat, with an overall survival rate of less …